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suitability of the recommendation to re-
classify malignant pleural effusion as
M1a, and, therefore, stage IV; and the
concern of classifying contralateral nod-
ules as M1a, disregarding the possibility
that some of these nodules may be second
primary tumors.
The criteria of the ISC to propose
changes to the present TNM classifica-
tion was based on survival differences
and clinical judgment. The issues Dr.
Barbieri et al. refer to in their letter were
intensively discussed. For most propos-
als, more than one possibility was avail-
able, i.e., to retain the descriptor in the
existing category, but identified by al-
phabetical subscripts, as Dr. Barbieri et
al. propose, or to allow descriptors to
move to a category containing other de-
scriptors with a similar prognosis. Regard-
ing malignant pleural effusion, it was
thought that, in most cases, it was the
consequence of metastatic spread in the
pleura. Malignant pleural effusion, al-
though confined to the chest, is treated as
disseminated disease. These two facts fa-
vored the proposal to reclassify it as M1
disease, instead of maintaining it in the T4
category. However, the proposal of Dr.
Barbieri et al. to reclassify it as T4b and
transfer this category to stage IV is also
valid was considered by the ISC, but was
not chosen to avoid the complexity of the
resulting TNM subsets.
The problem with additional nod-
ules in the same lobe, in another ipsilat-
eral lobe, and in the contralateral lung is
unsolved and will require a large num-
ber of well-registered cases. All of these
nodules, now proposed to be classified
as T3, T4, and M1a, respectively, can be
second primaries, metastasis, or non-
neoplastic disease. There rarely is pre-
operative pathologic diagnosis of these
additional nodules and, even postopera-
tively, unless they have different cell
types, second primaries and metastasis
are practically impossible to differenti-
ate with routine pathologic techniques.
The ISC is well aware of this fact and
for the prospective collection of data,
which will be used to inform the eighth
edition of the TNM classification, a de-
tailed dataset has been designed, includ-
ing molecular studies where they are
available. We hope that the prospective
project of the ISC will bring some light
to this difficult problem. In the mean-
time, we must keep in mind that the
TNM classification suggests but does
not dictate a certain type of treatment for
each TNM category. Therefore, the fact
that contralateral nodules are classified as
M1a disease does not preclude surgical
treatment if both the primary tumor and
the contralateral nodule are deemed com-
pletely resectable, and the patient is ade-
quately fit for the planned operation. We
know now that if the contralateral nodule
is a second primary, it will have a better
prognosis than a metastatic nodule; and if
it is a metastasis, its prognosis will be
better than that of metastasis outside the
chest.
We thank Dr. Barbieri et al. for
their thoughtful comments and for their
interest in lung cancer staging.
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IASLC Lung Cancer
Staging Project—A
Radiologist Perspective
To the Editor:
We read recent articles from the
International Association for the Study
of Lung Cancer staging project (espe-
cially relating to T and N staging) with
interest.1,2 We commend the tremendous
work of the team and mostly support the
proposed new staging system. There are
at least three areas where we, as radiol-
ogists, feel that this system is subopti-
mal and find it difficult to stage patients
in day-to-day practice.
First, relating to T descriptor,
Lymphangitis carcinomatosis (LC), al-
though uncommon, is a distressing form
of metastatic lung cancer and has major
impact in quality of life with an unfavor-
able prognosis.3 LC can occur from lym-
phatic invasion from the primary tumor or
nodal spread.4 In other tumors, particu-
larly, spread is thought to be hematoge-
nous. Computed tomography (CT) is the
imaging modality of choice and in most
cases radiologists are the first to recognize
it. In the tumor, node, metastasis (TNM)
staging, there is no specific reference to
LC, and we have always felt it difficult to
give an accurate stage when present. In
our practice, most patients with LC have
advanced disease and are not candidates
for radical treatment. LC may be seen in
the same lobe as the primary lesion or may
involve other ipsilateral lobes or both
lungs. This is analogous to a satellite nod-
ule but is likely to carry a poorer progno-
sis. The histologic diagnosis of lym-
phangitis is often not confirmed.
With regards to the N stage, we
agree with your findings of prognostic
difference between single N1/N2 nodes
versus multiple N1/N2 nodes. There is
substantial heterogeneity in clinical pre-
sentation, treatment, and prognosis re-
lating to N2 disease.5 This has been
recognized previously and subgroups of
N2 disease have been proposed. At one
end of this spectrum there is occult N2
disease, not found on conventional imag-
ing workup with CT and CT/positron
emission tomography (PET), but found at
surgery after lymph node dissection. At
the other end is N2 disease invading sur-
rounding mediastinal structures, analo-
gous to T4 stage. The revised TNM in
such cases does not reflect the true picture
of the disease. Nodal disease invading
mediastinal structures is analogous to T4
for the primary tumor stage. It may often
be difficult on CT where there is contigu-
ous disease to differentiate where the pri-
mary lesion stops and nodal disease starts.
Historically, CT has been the
primary investigation with its well-
recognized limitations. The introduc-
tion of PET and then CT/PET gives
more accurate information and is in-
creasingly used in routine staging if
patient is fit for radical therapy. The T
stage may be expected to take account
of metabolic activity in the tumor
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(Standard uptake value level). Equally in-
tense uptake in N2 groups is likely to have
a poorer prognosis than low-level single
station uptake. A suspicious contralateral
pulmonary nodule seen on CT is likely to
be more significant if it shows increased
uptake on CT/PET imaging.
If there is sufficient evidence, we
would ask the authors to see if these
unrepresented but well-recognized areas
could be incorporated into the revised
staging scheme. Future staging revisions
may need to incorporate the developing
prognostic information available from
anatomic and particularly metabolic im-
aging techniques.
J. Vimal Raj, MBBS, FRCR
Richard Coulden, FRCR, FRCP
James Entwisle, MBBS, MRCP, FRCR
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Reply to “Cancer
Staging
Correspondence 2”
In Reply:
We thank Drs Raj, Coulden, and
Entwistle for their interest in the Interna-
tional Association for the Study of Lung
Cancer (IASLC) Staging Project, their
kind comments and insightful questions.
Our recommendations for the 7th
Edition of tumor, node, metastasis
(TNM)1 were based upon the largest
database ever accumulated for the study
of Lung Cancer.2 It was a global effort
with colleagues from 46 data sources in
over 19 countries contributing data on
cases treated by all modalities of care,
enrolled over a relatively short period
from 1990 to 2000. However, when col-
lecting data retrospectively to build a
large database as quickly as possible one
has to take what data is available. Much
of the data with which we were provided
had been collected for other purposes,
such as clinical trials, and the staging
data collected was often limited to those
fields shown to be important in earlier
editions of TNM. Consequently, there
were many issues that we would have
wished to evaluate on which we had no
data. Many of these areas will be in-
cluded in the prospective database in-
tended as the next phase in this project.
The amount of detail that we can collect
will be dependent upon the level of
funding we obtain and upon identifying
appropriate collaborators who are able
to supply the minimum dataset.
We agree that the issue of lym-
phangitis identified by Raj and colleagues
is inadequately covered by the “optional
descriptors” for lymphatic invasion pres-
ently offered in the 6th Edition of either
the International Union Against Cancer
(UICC) TNM Classification of Malignant
Tumors3 or the American Joint Commit-
tee on Cancer (AJCC) Manual of Cancer
Staging.4 We hope to study this in more
detail in the prospective data base.
Our N-descriptors subcommittee
has reported the results of exploratory
analyses covering the prognostic role of
involvement of individual lymph nodes
and various combinations of nodal sta-
tions.5 In addition, this group has devel-
oped an “IASLC” nodal chart, about to
be submitted to the Journal of Thoracic
Oncology, which for the first time will
reconcile the differences between the
“Naruke” nodal chart6 and that of
“Mountain and Dressler.”7 These devel-
opments should allow our prospective
data base better to unravel the prognos-
tic interaction between the position and
bulk of involved lymph nodes. We in-
tend also to collect data on the size of
the most relevant nodal deposit in our
prospective data base.
Sadly in clinical staging the deci-
sion as to how much of a bulky tumor
mass represents primary tumor and how
much is due to nodal disease will remain a
judgment call. General rule 4, however,
suggests that “if there is doubt concerning
the correct T, N, or M category to which a
particular case should be allotted, then the
lower (i.e., less advanced) category should
be chosen. This will also be reflected in
the stage grouping.”
Positron emission tomography
scanning was not widely available dur-
ing the period of our data collection. The
European Lung Cancer Working Party,
on our behalf, undertook a meta-analysis
of the prognostic significance of the
maximum standardized uptake value in
the primary tumor at presentation, re-
cently published in the Journal of Tho-
racic Oncology.8 Our prospective data-
base will allow much more thorough
assessment of the prognostic informa-
tion available with positron emission to-
mography scanning.
Finally, we would like to take this
opportunity to inform our colleagues in
the lung cancer community of the TNM
Helpdesk available by following the links
at www.uicc.org. This resource allows
one to direct questions to experts in the
field of staging and lung cancer, and is
monitored by the UICC for proposals for
future revisions.
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